Wiebke Albrecht1. 1. IfADo - Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund, Ardeystr. 67, D-44139 Dortmund, Germany.
Recently Christian Hudert and colleagues from the Charité in Berlin published a study about genetic determinants in pediatric non-alcoholic liver disease (Hudert et al., 2018[9]). Non-alcoholic fatty liver disease (NAFLD), the most frequent chronic liver disease in children, is known to be strongly influenced by genetic factors (Nobili et al., 2016[14]; Schwimmer et al., 2006[17]; Makkonen et al., 2009[12]; Anstee et al., 2016[2]). However, genetic determinants of a portal/zone-1 pattern of steatosis in children are not yet known. This would be important, because a portal/zone-1 pattern of steatosis leads to an increased risk of disease progression to fibrosis (Africa et al., 2018[1]; Mann et al., 2016[13]). To address this question, the authors established the Berlin adolescence NAFLD cohort (BaNA) and studied a set of single nucleotide polymorphisms. Interestingly, a variant of the retinyl-palmitate lipase PNPLA3 (rs738409) was associated with a periportal pattern of steatosis and also with an increased risk of progression to fibrosis (Hudert et al., 2018[9]). Therefore, obesechildren with the PNPLA3 variant may be candidates for a more intensive clinical follow-up and intervention.Due to the current increase in the incidence of liver diseases a better understanding of their pathophysiology is of major importance (Jansen et al., 2017[11]; Vartak et al., 2016[20]; Hammad et al., 2014[7]; Hassan, 2016[8]; Stöber, 2016[18]; Bolt, 2017[3]; Ekhlasi et al., 2017[5]). For this purpose systems modeling as well as the analysis of expression patterns in relation to a phenotype represent frequently applied tools (Godoy et al., 2016[6]; Crespo Yanguas et al., 2016[4]; Jain et al., 2016[10]; Saleem et al., 2016[15]; Schenk et al., 2017[16]; Thiel et al., 2015[19]). The newly established BaNA cohort of adolescent NAFLD with its careful phenotyping and availability of proteome data is an important milestone for a better understanding of disease progression in steatosis.
Authors: Christoph Thiel; Sebastian Schneckener; Markus Krauss; Ahmed Ghallab; Ute Hofmann; Tobias Kanacher; Sebastian Zellmer; Rolf Gebhardt; Jan G Hengstler; Lars Kuepfer Journal: J Pharm Sci Date: 2014-11-12 Impact factor: 3.534
Authors: Seddik Hammad; Stefan Hoehme; Adrian Friebel; Iris von Recklinghausen; Amnah Othman; Brigitte Begher-Tibbe; Raymond Reif; Patricio Godoy; Tim Johann; Amruta Vartak; Klaus Golka; Petru O Bucur; Eric Vibert; Rosemarie Marchan; Bruno Christ; Steven Dooley; Christoph Meyer; Iryna Ilkavets; Uta Dahmen; Olaf Dirsch; Jan Böttger; Rolf Gebhardt; Dirk Drasdo; Jan G Hengstler Journal: Arch Toxicol Date: 2014-04-19 Impact factor: 5.153
Authors: Patricio Godoy; Agata Widera; Wolfgang Schmidt-Heck; Gisela Campos; Christoph Meyer; Cristina Cadenas; Raymond Reif; Regina Stöber; Seddik Hammad; Larissa Pütter; Kathrin Gianmoena; Rosemarie Marchan; Ahmed Ghallab; Karolina Edlund; Andreas Nüssler; Wolfgang E Thasler; Georg Damm; Daniel Seehofer; Thomas S Weiss; Olaf Dirsch; Uta Dahmen; Rolf Gebhardt; Umesh Chaudhari; Kesavan Meganathan; Agapios Sachinidis; Jens Kelm; Ute Hofmann; René P Zahedi; Reinhard Guthke; Nils Blüthgen; Steven Dooley; Jan G Hengstler Journal: Arch Toxicol Date: 2016-06-23 Impact factor: 5.153